



25 March 2026

Ms. Yulia Gurdina  
ASX Compliance Pty Limited  
Level 6, 20 Bridge Street,  
Sydney NSW 2000

Delivered via email: [yulia.gurdina@asx.com.au](mailto:yulia.gurdina@asx.com.au)

Dear Yulia,

### **RESPONSE TO PRICE QUERY**

In reference to your letter of 25 March 2026, regarding the price and volume of the Company's securities, the response to your queries in number order is as follows:

1. The Company is not aware of any price sensitive information that has not been announced, which is an explanation for the recent trading in its securities.
2. Not Applicable.
3. The Company is aware that Lumos Diagnostics Holdings Ltd (**ASX: LDX**) entered a trading halt pending an announcement to the market in relation to an update on the FDA response to the FebriDx® CLIA waiver application.

As previously disclosed to the market, LDX's FebriDx® test exclusively utilises Atomo's patented Pascal cassette to deliver improved usability and reliability in the hands of users.

As noted in question 1, the Company is unaware of the details of the response from the FDA in respect of the FebriDx® CLIA waiver application. As such the Company is currently unable to determine the impact of the FDA response to the Company but will continue to engage with LDX and provide an update to the market when possible.

4. It is confirmed that the Company is in compliance with the disclosure provisions of the Listing Rules, and in particular Listing Rule 3.1.
5. It is confirmed that the responses to the questions above have been authorised and approved by the Board of the Company.

Please contact me if you require any further information concerning this matter.

Yours sincerely,

Mathew Watkins  
Company Secretary

25 March 2026

Mr Mathew Watkins  
Company Secretary  
Atomo Diagnostics Limited  
Level 1, 3-5 George Street  
LEICHHARDT NSW 2040

By email

Dear Mr Watkins

### **Atomo Diagnostics Limited ('AT1'): Price Query**

ASX refers to the following:

- A. The change in the price of AT1's securities from a low of \$0.035 at the close of trading on 24 March 2026 to a high of \$0.041 today at the time of writing.
- B. The significant increase in the volume of AT1's securities traded today, 25 March 2026.

### **Request for information**

In light of this, ASX asks AT1 to respond separately to each of the following questions and requests for information:

1. Is AT1 aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
  - (a) Is AT1 relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in AT1's securities would suggest to ASX that such information may have ceased to be confidential and therefore AT1 may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
  - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
  - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that AT1 may have for the recent trading in its securities?
4. Please confirm that AT1 is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that AT1's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of AT1 with delegated authority from the board to respond to ASX on disclosure matters.

### **When and where to send your response**

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **3:30 PM AEDT on Wednesday, 25 March 2026**.

---

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, AT1's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require AT1 to request a trading halt immediately.

Your response should be sent by e-mail to **ListingsComplianceSydney@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow us to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

### **Trading halt**

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in AT1's securities under Listing Rule 17.1. If you wish to request a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts and Voluntary Suspensions*.

### **Suspension**

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in AT1's securities under Listing Rule 17.3.1.

### **Listing Rules 3.1 and 3.1A**

In responding to this letter, you should have regard to AT1's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*. It should be noted that AT1's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

### **Release of correspondence between ASX and entity**

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A. The usual course is for correspondence to be released to the market.

Regards

---

ASX Compliance